DBV Technologies SA (DBVT)
0.469
-0.02
(-3.91%)
USD |
NASDAQ |
Nov 22, 16:00
0.4662
0.00 (0.00%)
After-Hours: 20:00
DBV Technologies Cash from Financing (Quarterly): 0.007M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.007M |
| June 30, 2024 | -0.033M |
| March 31, 2024 | -0.062M |
| December 31, 2023 | -0.189M |
| September 30, 2023 | -0.837M |
| June 30, 2023 | 7.807M |
| March 31, 2023 | -0.014M |
| December 31, 2022 | -0.283M |
| September 30, 2022 | -0.818M |
| June 30, 2022 | 195.35M |
| Date | Value |
|---|---|
| March 31, 2022 | -0.129M |
| December 31, 2021 | 0.377M |
| September 30, 2021 | -1.174M |
| June 30, 2021 | 0.631M |
| March 31, 2021 | 0.44M |
| December 31, 2020 | -0.076M |
| September 30, 2020 | -1.048M |
| June 30, 2020 | 0.061M |
| March 31, 2020 | 150.61M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.174M
Minimum
Sep 2021
195.35M
Maximum
Jun 2022
18.45M
Average
-0.033M
Median
Jun 2024
Cash from Financing (Quarterly) Benchmarks
| Edap TMS SA | 0.6422M |
| Genfit SA | -- |
| Cellectis SA | -4.218M |
| Adaptimmune Therapeutics PLC | 25.00M |
| Akari Therapeutics PLC | -0.443M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -22.46M |
| Cash from Investing (Quarterly) | -0.109M |
| Free Cash Flow | -108.72M |
| Free Cash Flow Per Share (Quarterly) | -0.2376 |
| Free Cash Flow Yield | -241.1% |